Critics Fume as Big Pharma Funds Drug Studies

'The evidence base has been perverted,' expert says
By Neal Colgrass,  Newser Staff
Posted Nov 25, 2012 1:25 PM CST
Critics Fume as Big Pharma Funds Drug Studies
This Thursday, Dec. 29, 2011 photo shows the entrance to the editorial offices of the New England Journal of Medicine in Boston.   (AP Photo/Michael Dwyer)

Think studies of new drugs in the New England Journal of Medicine are unassailable? Experts are beginning to wonder, because pharmaceutical companies pay academics to conduct many of those studies—and the approval of high-profile drugs like Vioxx, Avandia, and Celebrex has led to thousands of deaths, the Washington Post reports. There's no proof that academics paid by Big Pharma altered their findings, and drug companies insist they play fair, but one analysis shows that industry-sponsored studies are 3.6 times more likely to approve a drug. "Unfortunately, the entire evidence base has been perverted," says a Yale professor.

What's more, drug companies are moving trials from nonprofit academic hospitals to for-profit organizations—where, critics say, corporate influence is far more likely. A Senate investigation into GlaxoSmithKline has already uncovered evidence that the company influenced studies of its diabetes drug, Avandia, to disguise potential heart dangers. And Journal editor Jeffrey Drazen is caught in the middle: "I lie awake at night because I know somebody somewhere is trying to pull a fast one on me," he says. "Have we plugged every leak?" One proposed solution: forcing drug companies to release all of their findings, pro and con—a move now being promoted by the European Medicines Agency. (Read more GlaxoSmithKline stories.)

We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.
Get the news faster.
Tap to install our app.
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.